Santhera is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule products for the treatment of orphan neuromuscular diseases, an area of high unmet medical needs.

Santhera has three compounds in development for seven orphan neuromuscular indications. Catena® is Santhera's first product, approved under conditions in Canada for symptomatic treatment of Friedreich's Ataxia.

Santhera is currently recruiting patients for clinical studies in Duchenne Muscular Dystrophy, MELAS and Primary Progressive Multiple Sclerosis.